The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)

Cancer statistics, 2012

Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone

Christopher D.�M. Fletcher, Krisjnan Unni, Fredrik Mertens · Lund University Publications (Lund University) · 2002 · 2.8K citations

Medicine, Oncology, Pathology +17

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text

Medicine, Oncology, Pharmacology +15

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Armando Santoro, T Türsz, Henning T. Mouridsen et al. · Journal of Clinical Oncology · 1995 · 530 citations

Medicine, Oncology, Pharmacology +14

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Axel Le Cesne, Jean‐Yves Blay, Ian Judson et al. · Journal of Clinical Oncology · 2005 · 421 citations

Medicine, Oncology, Pharmacology +16